Abstract
Liver grafts discarded for transplantation because of macrosteatosis can constitute a valuable source of human hepatocytes for in vitro metabolic and pharmacotoxicological studies or for therapeutic applications. A condition for using hepatocyte suspensions for these purposes is the preservation of their metabolic competence and, particularly, drug-metabolizing enzymes. A reduction in microsomal cytochrome P450 (P450) activities was observed in fatty livers (>40% steatosis) with respect to normal tissue. Similarly, decreased levels of 7-ethoxycoumarin O-deethylation and testosterone metabolism were observed in human hepatocyte cultures prepared from steatotic liver tissue. To clarify the potential impact of lipid accumulation on human hepatic P450 enzymes, we have used an in vitro model of “cellular steatosis” by incubation of cultured hepatocytes with increasing concentrations (0.25–3 mM) of long-chain free fatty acids (FFA). A dose-dependent accumulation of lipids in the cytosol is induced by FFA mixture. Hepatocytes exposed to 1 mM FFA for 14 h showed lower activity values of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 enzymes than nontreated hepatocytes (about 45–65% reduction). This treatment also produced significant decreases in CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 mRNA to about 55 to 75% of mRNA levels in control cells. Our results suggest that although human hepatocytes isolated from steatotic liver show reduced P450 activities, they are metabolically competent and can be used for drug metabolism studies.
Footnotes
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
This work was supported by the ALIVE Foundation, funds of the Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III of Spain Grant 03/0339, and the European Commission Grant LSHB-CT-2004-504761.
-
doi:10.1124/dmd.106.009670.
-
ABBREVIATIONS: P450, cytochrome(s) P450; FFA, free fatty acid(s); OHT, hydroxytestosterone; PBS, phosphate-buffered saline; MROD, 7-methoxyresorufin O-demethylation; ECOD, 7-ethoxycoumarin O-deethylation; CH, coumarin 7-hydroxylation; D4OH, diclofenac 4′-hydroxylation; C6OH, chlorzoxazone 6-hydroxylation; CPR, NADPH-P450 reductase; GT, UDP-glucuronyltransferase; BROD, 7-benzoxyresorufin O-debenzylation; PHE, phenacetin O-deethylation; MID, midazolam 1′-hydroxylation; BUF, bufuralol 1′-hydroxylation; MS/MS, tandem mass spectrometry.
- Received February 7, 2006.
- Accepted June 8, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|